<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35158095</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>09</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-9919</ISSN><JournalIssue CitedMedium="Internet"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Infectious diseases now</Title><ISOAbbreviation>Infect Dis Now</ISOAbbreviation></Journal><ArticleTitle>Long COVID-19 symptoms: Clinical characteristics and recovery rate among non-severe outpatients over a six-month follow-up.</ArticleTitle><Pagination><StartPage>165</StartPage><EndPage>169</EndPage><MedlinePgn>165-169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.idnow.2022.02.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-9919(22)00038-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To describe persistent symptoms in long COVID-19 non-severe outpatients and report the 6-month clinical recovery (CR) rate.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Observational study enrolling outpatients (&#x2265;&#xa0;18 years) with confirmed non-severe COVID-19 (positive nasopharyngeal RT-PCR or presence of SARS-CoV-2 antibodies) who consulted for persistent symptoms after the first pandemic wave (March-May 2020). CR was assessed at the 6-month visit and defined as complete (no symptom), partial (persistent symptoms of lower intensity) or lack of recovery (no improvement).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-three patients (79% women, mean age: 48 years) enrolled; main symptoms (mean 81 days after acute infection): asthenia/myalgia (77%), dyspnea (51%), headaches (35%), cough (33%). At 6 months (n=56), 30% had complete, 57% partial, and 13% lack of recovery. The proportion of patients with&gt;2 persistent symptoms was 26% at 6 months (main symptoms: dyspnea [54%] and asthenia/myalgia [46%]).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We observed a slow but high recovery rate at 6 months among these outpatients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Seang</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France. Electronic address: sophie.seang@aphp.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Itani</LastName><ForeName>O</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>AP-HP, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monsel</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AP-HP, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdi</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Sorbonne University, Virology Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcelin</LastName><ForeName>A G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Sorbonne University, Virology Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valantin</LastName><ForeName>M A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palich</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fay&#xe7;al</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pourcher</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katlama</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tubiana</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sorbonne University, Infectious Diseases Department, Piti&#xe9;-Salp&#xea;tri&#xe8;re Hospital, AP-HP, Pierre-Louis Epidemiology and Public Health institute (iPLESP), Inserm 1136, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Infect Dis Now</MedlineTA><NlmUniqueID>101775152</NlmUniqueID><ISSNLinking>2666-9919</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001247" MajorTopicYN="N">Asthenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004417" MajorTopicYN="N">Dyspnea</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063806" MajorTopicYN="N">Myalgia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010045" MajorTopicYN="N">Outpatients</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Long COVID-19</Keyword><Keyword MajorTopicYN="N">Outpatients</Keyword><Keyword MajorTopicYN="N">Post-infectious disorders</Keyword><Keyword MajorTopicYN="N">Recovery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>14</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>2</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35158095</ArticleId><ArticleId IdType="pmc">PMC8832844</ArticleId><ArticleId IdType="doi">10.1016/j.idnow.2022.02.005</ArticleId><ArticleId IdType="pii">S2666-9919(22)00038-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int.</Citation></Reference><Reference><Citation>COVID-19 Coronavirus Pandemic. https://www.worldometers.info/coronavirus/#countries.</Citation></Reference><Reference><Citation>Guan W.J., et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J Intern Med. 2020;288:335&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevinsky J.R., et al. Late conditions diagnosed 1-4 months following an initial COVID-19 encounter: a matched cohort study using inpatient and outpatient administrative data - United States March 1-June 30 2020. Clin Infect Dis. 2021 doi: 10.1093/cid/ciab338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab338</ArticleId><ArticleId IdType="pmc">PMC8135331</ArticleId><ArticleId IdType="pubmed">33909072</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund L.C., et al. Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study. Lancet Infect Dis. 2021;21:1373&#x2013;1382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8110209</ArticleId><ArticleId IdType="pubmed">33984263</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., et al. Post-COVID-19 symptoms 6&#xa0;months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021;27:1507&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8180450</ArticleId><ArticleId IdType="pubmed">34111579</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27:601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>EUA Authorized Serology Test Performance. https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance.</Citation></Reference><Reference><Citation>https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1</Citation></Reference><Reference><Citation>Cousyn L., et al. Olfactory and gustatory dysfunctions in COVID-19 outpatients: a prospective cohort study. Infect Dis Now. 2021 doi: 10.1016/j.idnow.2021.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.03.004</ArticleId><ArticleId IdType="pmc">PMC7983360</ArticleId><ArticleId IdType="pubmed">33766735</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen M.S., et al. Long COVID in the Faroe Islands - a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2020 doi: 10.1093/cid/ciaa1792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1792</ArticleId><ArticleId IdType="pmc">PMC7799340</ArticleId><ArticleId IdType="pubmed">33252665</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., et al. Characterising long COVID: a living systematic review. BMJ Glob Health. 2021;6:e005427.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020;15:e0240784.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandler C.X., et al. Long COVID and post-infective fatigue syndrome: a review. Open Forum Infect Dis. 2021;8:ofab440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8496765</ArticleId><ArticleId IdType="pubmed">34631916</ArticleId></ArticleIdList></Reference><Reference><Citation>HAS. Rapid responses in the context of COVID-19 -Management of COVID+ patients in Physical Medicine and Rehabilitation (MPR), and on return home. https://www.has-sante.fr/upload/docs/application/pdf/2020-05/388_reponse_rapide_covid19__mpr_srr_03-05-20_anglaise_2020-05-05_14-50-42_202.pdf.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>